Vivus is the subject of a buyout rumor for $640 million.
It is being reported that Aspen Investments, which could have an almost 10% stake in Vivus already, is set to offer $640 million for Vivus.
It is said that the offer will be conditional and non-binding.
It is anticipated that the offer will be submitted to the Vivus Board of Directors by June 13, 2014.
There are several things here for investors to consider.
First and foremost is that an offer has not yet been made.
At the moment, all that we have for information is that Aspen Investment is considering the submission of an offer.
For further deal information visit Current Agreements (subscription required)
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity